Stenland Christopher J, Lee Douglas C, Brown Paul, Petteway Stephen R, Rubenstein Richard
Department of Pathogen Safety Research, Bayer Biological Products, Research Triangle Park, North Carolina 27709, USA.
Transfusion. 2002 Nov;42(11):1497-500. doi: 10.1046/j.1537-2995.2002.00216.x.
Therapeutic proteins derived from human plasma and other biologic sources have demonstrated an excellent safety record relative to the potential threat of transmissible spongiform encephalopathy (TSE) transmission. Previously, hamster-adapted scrapie was used as a model agent to assess TSE clearance in purification steps leading to the isolation of biopharmaceutical proteins. The current study investigated the validity of hamster scrapie as a model for human TSE clearance studies. The partitioning of the pathogenic forms of the prion protein associated with human variant CJD (PrP(vCJD)), human sporadic CJD (PrP(sCJD)) and Gerstmann-Sträussler-Scheinker (PrP(GSS)) syndrome was compared to the partitioning of hamster scrapie (PrP(Sc)) in three plasma protein purification steps. Sheep scrapie (PrP(Sc)) was similarly evaluated.
The starting materials for three plasma protein purification steps, cryoseparation, 3 percent PEG separation, and 11.5 percent PEG separation, were spiked with brain homogenates containing human PrP(vCJD), human PrP(sCJD), human PrP(GSS), sheep PrP(Sc), and hamster 263K PrP(Sc). The partitioning of the pathogenic form of the PrP was analyzed.
Clearance of the pathogenic form of the PrP was measured relative to the effluent fraction. Regardless of the source of the pathogenic prion, clearance was similar to hamster PrP(Sc). A nominal amount of clearance (approx., 1 log), an intermediate amount of clearance (approx., 2 log), and a substantial amount of clearance (> or = 3 log) were observed for the cryoseparation, 3 percent PEG separation, and 11.5 percent PEG separation steps, respectively. In the latter step, no PrP was detected in the effluents.
These data demonstrate that human prions, including vCJD prions, can be removed during the purification of human therapeutic proteins and indicate that partitioning of human prions is similar to that observed in the hamster scrapie model.
相对于可传播性海绵状脑病(TSE)传播的潜在威胁,源自人血浆和其他生物来源的治疗性蛋白质已显示出出色的安全记录。以前,仓鼠适应型瘙痒病被用作模型试剂,以评估在导致生物制药蛋白质分离的纯化步骤中TSE的清除情况。当前研究调查了仓鼠瘙痒病作为人类TSE清除研究模型的有效性。将与人类变异型克雅氏病(PrP(vCJD))、人类散发性克雅氏病(PrP(sCJD))和格斯特曼-施特劳斯勒-谢克尔综合征(PrP(GSS))相关的朊病毒蛋白致病形式的分配情况,与仓鼠瘙痒病(PrP(Sc))在三个血浆蛋白纯化步骤中的分配情况进行了比较。对绵羊瘙痒病(PrP(Sc))也进行了类似评估。
在三个血浆蛋白纯化步骤(冷冻分离、3%聚乙二醇分离和11.5%聚乙二醇分离)的起始材料中,加入含有人类PrP(vCJD)、人类PrP(sCJD)、人类PrP(GSS)、绵羊PrP(Sc)和仓鼠263K PrP(Sc)的脑匀浆。分析了PrP致病形式的分配情况。
相对于流出部分测量了PrP致病形式的清除情况。无论致病朊病毒的来源如何,清除情况与仓鼠PrP(Sc)相似。在冷冻分离、3%聚乙二醇分离和11.5%聚乙二醇分离步骤中,分别观察到名义清除量(约1个对数)、中等清除量(约2个对数)和大量清除量(≥3个对数)。在最后一步中,流出物中未检测到PrP。
这些数据表明,包括vCJD朊病毒在内的人类朊病毒可在人类治疗性蛋白质纯化过程中被去除,并表明人类朊病毒的分配情况与仓鼠瘙痒病模型中观察到的情况相似。